Popular filter options for medullary thyroid cancer trials
MTC Clinical Trials
View 10 MTC medical studies.
Tyrosine Kinase Inhibitor
Selpercatinib for Solid Tumors
This trial is designed to study the effects of a new drug, selpercatinib, on various types of solid tumors. The goal is to see if it is safe and tolerable, how it is metabolized, and if it has any preliminary anti-tumor activity.
Cancer Vaccine
GI-6207 for Medullary Thyroid Cancer
Background: - GI-6207 is an experimental cancer vaccine made with baker's yeast. The yeast has been modified to help the immune system target a protein called CEA. CEA is found on the surface of some kinds of tumor cells, including thyroid cancer cells. Researchers want to see if GI-6207 can encourage the body's immune system to attack and kill tumor cells that contain the CEA protein. They will test to see whether this vaccine is a safe and effective treatment for medullary thyroid cancer that has not responded to earlier treatments. Objectives: - To test the safety and effectiveness of the GI-6207 vaccine for advanced medullary thyroid cancer. Eligibility: - Individuals at least 18 years of age who have medullary thyroid cancer that has not responded to earlier treatments. Design: Participants will be screened with a physical exam and medical history. They will provide blood and tumor samples and have an imaging study of the neck and chest. They will also have a skin test to make sure that they are not allergic to the yeast in the vaccine. Participants will be divided into two groups. One group will start to take GI-6207 immediately for 1 year. The second group will have 6 months of monitoring and tests with no vaccine, and then will take GI-6207 for 1 year. GI-6207 will be given every other week for the first seven visits (about 3 months), and then monthly for the remaining year of treatment. It will be given as injections beneath the arm and in the upper thigh. These locations will help the vaccine enter the lymph nodes and reach the immune system more quickly. Participants will be monitored with frequent blood and urine tests and imaging studies. Participants will have regular follow-up visits after their year of study vaccines.
Behavioural Intervention
CASAD for Diarrhea
Diarrhea in patients with MTC (Medullary Thyroid Cancer) can be debilitating and, in some cases life threatening. Findings in such patients include volume depletion, renal insufficiency, and electrolyte disorders. Diarrhea can also lead to increased cost of care, reduced quality of life, and treatment delays. Not all patients benefit from conventional anti-diarrheal therapy. CASAD is proven to reduce diarrhea in humans and animals. Clays have water-binding effects, increase the absorptive capacity of the intestinal mucosa, and absorb the excess cytokines which are possible mechanisms of diarrhea in MTC. In this study, we will investigate if starting 1 g CASAD three times a day will ameliorate the severity of diarrhea in patients with MTC. Diarrhea in patients with MTC can be debilitating and, in some cases life threatening. Findings in such patients include volume depletion, renal insufficiency, and electrolyte disorders. We hypothesize that adding CASAD 3 grams/day will reduce the incidence and ameliorate the severity of diarrhea in patients with MTC.
Thyroid Carcinoma Clinical Trials
View 6 Thyroid Carcinoma medical studies.
Tyrosine Kinase Inhibitor
Vandetanib for Thyroid Cancer
This trial is investigating the effects of the drug ZD6474 on patients with medullary thyroid cancer, in order to learn more about the drug's efficacy, side effects, and how it works in the human body.
Metastatic Medullary Thyroid Cancer Clinical Trials
View 14 metastatic medullary thyroid cancer medical studies.
Tyrosine Kinase Inhibitor
Selpercatinib for Solid Tumors
This trial is designed to study the effects of a new drug, selpercatinib, on various types of solid tumors. The goal is to see if it is safe and tolerable, how it is metabolized, and if it has any preliminary anti-tumor activity.
Tyrosine Kinase Inhibitor
Vandetanib for Thyroid Cancer
This trial is investigating the effects of the drug ZD6474 on patients with medullary thyroid cancer, in order to learn more about the drug's efficacy, side effects, and how it works in the human body.
Medullary Thyroid Cancer Clinical Trials With No Placebo
View 14 medullary thyroid cancer medical studies that do not have a placebo group.
Tyrosine Kinase Inhibitor
Selpercatinib for Solid Tumors
This trial is designed to study the effects of a new drug, selpercatinib, on various types of solid tumors. The goal is to see if it is safe and tolerable, how it is metabolized, and if it has any preliminary anti-tumor activity.
Cancer Vaccine
GI-6207 for Medullary Thyroid Cancer
Background: - GI-6207 is an experimental cancer vaccine made with baker's yeast. The yeast has been modified to help the immune system target a protein called CEA. CEA is found on the surface of some kinds of tumor cells, including thyroid cancer cells. Researchers want to see if GI-6207 can encourage the body's immune system to attack and kill tumor cells that contain the CEA protein. They will test to see whether this vaccine is a safe and effective treatment for medullary thyroid cancer that has not responded to earlier treatments. Objectives: - To test the safety and effectiveness of the GI-6207 vaccine for advanced medullary thyroid cancer. Eligibility: - Individuals at least 18 years of age who have medullary thyroid cancer that has not responded to earlier treatments. Design: Participants will be screened with a physical exam and medical history. They will provide blood and tumor samples and have an imaging study of the neck and chest. They will also have a skin test to make sure that they are not allergic to the yeast in the vaccine. Participants will be divided into two groups. One group will start to take GI-6207 immediately for 1 year. The second group will have 6 months of monitoring and tests with no vaccine, and then will take GI-6207 for 1 year. GI-6207 will be given every other week for the first seven visits (about 3 months), and then monthly for the remaining year of treatment. It will be given as injections beneath the arm and in the upper thigh. These locations will help the vaccine enter the lymph nodes and reach the immune system more quickly. Participants will be monitored with frequent blood and urine tests and imaging studies. Participants will have regular follow-up visits after their year of study vaccines.
Behavioural Intervention
CASAD for Diarrhea
Diarrhea in patients with MTC (Medullary Thyroid Cancer) can be debilitating and, in some cases life threatening. Findings in such patients include volume depletion, renal insufficiency, and electrolyte disorders. Diarrhea can also lead to increased cost of care, reduced quality of life, and treatment delays. Not all patients benefit from conventional anti-diarrheal therapy. CASAD is proven to reduce diarrhea in humans and animals. Clays have water-binding effects, increase the absorptive capacity of the intestinal mucosa, and absorb the excess cytokines which are possible mechanisms of diarrhea in MTC. In this study, we will investigate if starting 1 g CASAD three times a day will ameliorate the severity of diarrhea in patients with MTC. Diarrhea in patients with MTC can be debilitating and, in some cases life threatening. Findings in such patients include volume depletion, renal insufficiency, and electrolyte disorders. We hypothesize that adding CASAD 3 grams/day will reduce the incidence and ameliorate the severity of diarrhea in patients with MTC.
Frequently Asked Questions
Introduction to medullary thyroid cancer
What are the top hospitals conducting medullary thyroid cancer research?
Medullary thyroid cancer, a rare form of thyroid cancer that originates in the cells of the thyroid gland, has attracted the attention of top hospitals across different locations. In Duarte, California, City of Hope National Medical Center is currently conducting two active clinical trials for medullary thyroid cancer. While they may not have any previous trials recorded specifically for this condition, their expertise and dedication to cutting-edge research make them a valuable resource for patients seeking innovative treatments. Similarly, UCLA Medical Center in Los Angeles is also actively engaged in two ongoing trials for medullary thyroid cancer with no prior records. Their involvement highlights their commitment to exploring new options and improving outcomes for individuals affected by this disease.
Further up north in San Francisco's vibrant medical community lies UCSF Medical Center at Mission Bay, which shares the same commendable track record as its counterparts - undertaking two current medullary thyroid cancer trials without any past studies documented yet again reinforcing their commitment towards breakthroughs within such domain while serving patient population within surrounding areas.
Meanwhile in Jacksonville Florida Mayo Clinic-Jacksonville dedicates itself engaging simultaneously on 2 contemporary tests aiming forward strides though no concluded investigations can be found but nonetheless displaying eagerness persisting alongside esteemed institutions nationwide inventing novel ways tackling cases regarding MTC
Lastly but never least comes Emory University situated at Atlanta partaking similar role executing multiple experiments totaling around two presently working on possible solutions assisting MTC; alike remaining contenders historical data showcases zilch considering MTC however each demonstrates drive contributing advancement among scientific scope focusing upon this specific illness.
These top-tier hospitals are remarkable forces propelling progress against medullary thyroid cancer through extensive clinical trials aiming to uncover effective therapies and improve patient outcomes. The collective efforts demonstrated underscore both the challenges presented by this unique type of cancer and the unwavering dedication shown by medical professionals across diverse locations united under one common goal - advancing medicine and transforming lives.
Which are the best cities for medullary thyroid cancer clinical trials?
When it comes to medullary thyroid cancer clinical trials, several cities have emerged as leaders in research and development. Houston, Texas takes the lead with 6 active trials investigating promising treatments like Selpercatinib, Decision Aid, and LOXO-292. Boston, Massachusetts closely follows with 5 ongoing studies focusing on innovative approaches such as LOXO-292, Selpercatinib, and Regorafenib. Jacksonville, Florida; Saint Louis, Missouri; and Philadelphia, Pennsylvania also show significant contributions to the field with their respective active trials examining potential breakthroughs in treatment options for medullary thyroid cancer. These cities offer patients battling this rare form of thyroid cancer access to cutting-edge clinical trials that hold hope for improved outcomes and advancements in care.
Which are the top treatments for medullary thyroid cancer being explored in clinical trials?
Medullary thyroid cancer research is making strides in clinical trials, with two top treatments showing promise. Leading the way is selpercatinib, currently undergoing one active trial solely focused on medullary thyroid cancer. This novel treatment entered the scene in 2021 and has already shown potential for combating this type of cancer. Another noteworthy contender is decision aid, also being explored in one ongoing trial for medullary thyroid cancer. Its introduction to the medical field occurred back in 2019, and researchers are hopeful that it could offer new avenues for patients battling this specific form of thyroid cancer. With these advancements, there is renewed hope on the horizon for those affected by medullary thyroid cancer.
What are the most recent clinical trials for medullary thyroid cancer?
The field of medullary thyroid cancer research is making significant strides with recent clinical trials offering hope for improved treatment options. Noteworthy studies include the investigation of selpercatinib, a Phase 3 trial that commenced on February 11th, 2020. Another promising development is LOXO-292, which has progressed through Phase 1 and Phase 2 trials since May 2nd, 2017. Additionally, regorafenib's efficacy in treating medullary thyroid cancer was examined during a Phase 2 trial starting on January 1st, 2016. These advancements pave the way for enhanced therapeutic approaches to combat this form of cancer and bring about positive outcomes for patients in need.
What medullary thyroid cancer clinical trials were recently completed?
In April 2020, Epizyme, Inc. concluded a clinical trial investigating the efficacy of Tazemetostat in treating medullary thyroid cancer (MTC). This milestone represents an important step forward in the search for improved treatments for this specific type of thyroid cancer. The completion of this trial highlights the dedication and progress made by researchers to better understand and combat MTC, offering hope to individuals affected by this challenging disease.